Lasmiditan is a prescription medicine indicated for the acute treatment of migraine with or without aura in adults, among other approved uses. It is available as tablets for oral use. MedsAcross supplies Lasmiditan for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
REYVOW ® is indicated for the acute treatment of migraine with or without aura in adults. REYVOW ® is a serotonin (5-HT) 1F receptor agonist indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use REYVOW is not indicated for the preventive treatment of migraine.
Source: US FDA prescribing information
Lasmiditan binds with high affinity to the 5-HT 1F receptor. Lasmiditan presumably exerts its therapeutic effects in the treatment of migraine through agonist effects at the 5-HT 1F receptor, however, the precise mechanism is unknown.
Source: US FDA prescribing information
The recommended dose of REYVOW is 50 mg, 100 mg, or 200 mg taken orally, as needed. No more than one dose should be taken in 24 hours, and REYVOW should not be taken unless the patient can wait at least 8 hours between dosing and driving or operating machinery. A second dose of REYVOW has not been shown to be effective for the same migraine attack. The safety of treating an average of more than 4 migraine attacks in a 30-day period has not been established. REYVOW may be taken with or without food. Administer tablets whole, do not split, crush, or chew. The recommended dose is 50 mg, 100 mg, or 200 mg taken orally, as needed. No more than one dose should be taken in 24 hours. Administer tablets whole.
Source: US FDA prescribing information
None. None.
Source: US FDA prescribing information
Driving Impairment: Advise patients not to drive or operate machinery until at least 8 hours after taking each dose of REYVOW. Patients who cannot follow this advice should not take REYVOW. Patients may not be able to assess their own driving competence and the degree of impairment caused by REYVOW. Central Nervous System (CNS) Depression: REYVOW may cause CNS depression and should be used with caution if used in combination with alcohol or other CNS depressants. Serotonin Syndrome: Reactions consistent with serotonin syndrome were reported in patients treated with REYVOW. Discontinue REYVOW if symptoms of serotonin syndrome occur. Medication Overuse Headache: Detoxification may be necessary.
Source: US FDA prescribing information
The following clinically significant adverse reactions are described elsewhere in the labeling: Driving Impairment Central Nervous System Depression Serotonin Syndrome Medication Overuse Headache Most common adverse reactions (≥5% and > placebo) were dizziness, fatigue, paresthesia, and sedation.
Source: US FDA prescribing information
REYVOW may further lower heart rate when administered with heart rate lowering drugs. CNS Depressants Concomitant administration of REYVOW and alcohol or other CNS depressant drugs has not been evaluated in clinical studies. Because of the potential of REYVOW to cause sedation, as well as other cognitive and/or neuropsychiatric adverse reactions, REYVOW should be used with caution if used in combination with alcohol or other CNS depressants.
Source: US FDA prescribing information
Store at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
2 presentations of Lasmiditan, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Reyvow 100 mg tabletOral | Eli Lilly | US FDA | Available on request |
| Reyvow 50 mg tabletOral | Eli Lilly | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Yes, on request. MedsAcross lists 2 presentations of Lasmiditan and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Lasmiditan, including Reyvow.
Yes. The US FDA first approved Lasmiditan on 11 October 2019, according to Drugs@FDA.
Yes. Lasmiditan has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
No listed presentation of Lasmiditan is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Lasmiditan is classified under ATC code N02CC08 (Lasmiditan).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.